News
COTXF
0.170
NaN%
--
Weekly Report: what happened at ROQAF last week (0908-0912)?
Weekly Report · 09/15/2025 12:05
Weekly Report: what happened at ROQAF last week (0901-0905)?
Weekly Report · 09/08/2025 12:07
Weekly Report: what happened at ROQAF last week (0825-0829)?
Weekly Report · 09/01/2025 12:01
Weekly Report: what happened at ROQAF last week (0818-0822)?
Weekly Report · 08/25/2025 12:17
Weekly Report: what happened at ROQAF last week (0811-0815)?
Weekly Report · 08/18/2025 12:05
Weekly Report: what happened at ROQAF last week (0804-0808)?
Weekly Report · 08/11/2025 12:15
Weekly Report: what happened at ROQAF last week (0728-0801)?
Weekly Report · 08/04/2025 12:19
Weekly Report: what happened at ROQAF last week (0721-0725)?
Weekly Report · 07/28/2025 12:19
Weekly Report: what happened at ROQAF last week (0714-0718)?
Weekly Report · 07/21/2025 12:06
Weekly Report: what happened at ROQAF last week (0707-0711)?
Weekly Report · 07/14/2025 12:19
Weekly Report: what happened at ROQAF last week (0630-0704)?
Weekly Report · 07/07/2025 12:06
Weekly Report: what happened at ROQAF last week (0623-0627)?
Weekly Report · 06/30/2025 12:16
Weekly Report: what happened at ROQAF last week (0616-0620)?
Weekly Report · 06/23/2025 12:05
Weekly Report: what happened at ROQAF last week (0609-0613)?
Weekly Report · 06/16/2025 12:15
More
Webull provides a variety of real-time COTXF stock news. You can receive the latest news about COILED THERAPEUTICS PLC through multiple platforms. This information may help you make smarter investment decisions.
About COTXF
Roquefort Therapeutics PLC is a United Kingdom-based material biotech company. The Company is engaged in preclinical development of next generation medicines focused on hard-to treat cancers. The Company’s portfolio consists of over five novel patent-protected pre-clinical anti-cancer medicines. Its portfolio of medicines include Midkine antibodies with in vivo efficacy and toxicology studies, and orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics targeting solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significant in vivo efficacy, and MK cell therapy with direct and Natural Killer cell-mediated anti-cancer action. The Company has partnered with leading academic cancer research centers which complement its own in-house expertise and laboratory infrastructure.